- CSL Behring evaluates monoclonal Ab for respiratory distress
- GBC develops novel molecular testing kit for COVID-19
- Lipidor, Cadila to conduct Ph III study of anti-psoriasis candidate
- Daewoong Pharma expands influence across Asia
- BD launches rapid Ag test to detect SARS-CoV-2 in 15 mins
- Eisai to launch anti-insomnia drug in Japan
- CAREhab – Singapore Rehabilitation Conference 2020 goes digital this July
- Evive Biotech meets promising results at Global Ph III trial for neutropenia treatment
- Eisai's new Anti-insomnia drug Dayvigo approved in Hong Kong
- FDA approves Roche’s Phesgo for HER2-positive breast cancer
- Piramal Pharma acquires Solid Oral Dosage Drug Product Facility in Pennsylvania
- The EIU reports excess cancer mortality in many Asian countries
- "Effective Healthcare Communication in Digital Age" an opinion by Alcatel-Lucent
- Carmine Therapeutics teams up with Takeda for non-viral gene therapies
-
World | 20 March 2020 | Influencers
Eppendorf is investing disproportionately in expansion of its global locations, particularly in Asia
Congratulations on your new role. What are the main agendas behind the recently announced dual leadership at E...Read more
-
Korea | 08 July 2020 | News
Daewoong Pharma expands influence across Asia
Korea's Daewoong Pharmaceutical’s original botulinum toxin product Nabota is stepping up to expand its i...Read more
-
Australia | 08 July 2020 | News
CSL Behring evaluates monoclonal Ab for respiratory distress
Australia based CSL Limited's part, CSL Behring has announced that the first patient has been enrolled in...Read more
-
World | 05 March 2020 | News
FDA bans ESDs for self injurious behaviour
After careful consideration, the U.S. Food and Drug Administration (FDA) has published a final rule to ban ele...Read more
-
Europe | 06 March 2020 | News
Viroclinics Biosciences and DDL Diagnostic Lab join forces
Netherlands based Viroclinics Biosciences, a leading virology contract research organization, has announced th...Read more
Firms racing to develop antibody treatment for COVID-19
The Coronavirus COVID-19 has raged the world and has infected 8,993,659 cases and killed 469,587 (as of June 23, 2020. Source World Health Organization (WHO)). Pharma firms, scientists and governments all over the world are racing to find a cure for the virus. The entire world is waiting for the vaccine; Moderna’s mRNA vaccine will begin phase III study in July. Amidst all this, some biopharma companies are pushing to develop antibody based treatments for the virus. Does that have any merit? Why are firms putting billions of dollars into it when vaccines are the ultimate solution? Let’s find out.
